DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?

Genetic Vaccines and Therapy

Volumn 10, Issue , 2012, Pages

  Ahmad, Sarfraz ^a,c   Sweeney, Paul ^b   Sullivan, Gerald C ^a   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

^c NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN;

ANTIBODY TITER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOLYSIS; DNA IMMUNIZATION; DNA METHYLATION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG SAFETY; ENDOPLASMIC RETICULUM; EX VIVO GENE TRANSFER; FEASIBILITY STUDY; GENE TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO GENE TRANSFER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; TH1 CELL; TUMOR GROWTH;

ANIMALIA;

EID: 84867131602     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-10-9     Document Type: Review

References (63)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61:1079-1092. 10.1016/j.eururo.2012.02.054, 22424666.
2. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007, 56:81-87.
3. Schurko B, Oh WK. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol 2008, 5:506-507.
4. Coffey DS, Isaacs JT. Control of prostate growth. Urology 1981, 17:17-24.
5. Harada M, Noguchi M, Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 2003, 8:193-199. 10.1007/s10147-003-0332-x, 12955573.
6. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48:326-334. 10.1016/S0090-4295(96)00184-7, 8753752.
7. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997, 57:2321-2324.
8. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 2000, 164:1825-1829. 10.1016/S0022-5347(05)67114-5, 11025777.
9. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999, 59:5160-5168.
10. McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 1995, 6:375-385. 10.1016/1044-579X(95)90007-1, 8938276.
11. Yedavelli SP, Guo L, Daou ME, Srivastava PK, Mittelman A, Tiwari RK. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med 1999, 4:243-248.
12. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000, 6:1632-1638.
13. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894-3903.
14. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000, 38:208-217. 10.1159/000020281, 10895014.
15. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004, 91:688-694. 2364780, 15280930.
16. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. 10.1056/NEJMoa1001294, 20818862.
17. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8:108-120. 10.1038/nrc2326, 18219306.
18. Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010, 22:264-270. 10.1016/j.coi.2010.01.019, 20172703.
19. Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S. Current vaccination strategies for prostate cancer. Eur Urol 2012, 61(2):290-306. 10.1016/j.eururo.2011.09.020, 22001436.
20. Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K, Weiner DB. DNA vaccines for targeting bacterial infections. Expert Rev Vaccines 2010, 9:747-763. 10.1586/erv.10.57, 2962930, 20624048.
21. Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999, 190:1717-1722. 10.1084/jem.190.11.1717, 2195744, 10587362.
22. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003, 3:630-641. 10.1038/nri1150, 12974478.
23. Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000, 128:273-280. 10.1067/msy.2000.107421, 10923004.
24. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 1998, 17:3125-3135. 10.1038/sj.onc.1201736, 9872328.
25. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 2001, 7:882s-889s.
26. Oliveira SC, Rosinha GM, de-Brito CF, Fonseca CT, Afonso RR, Costa MC, Goes AM, Rech EL, Azevedo V. Immunological properties of gene vaccines delivered by different routes. Braz J Med Biol Res 1999, 32:207-214.
27. Moingeon P. Strategies for designing vaccines eliciting Th1 responses in humans. J Biotechnol 2002, 98:189-198. 10.1016/S0168-1656(02)00131-1, 12141986.
28. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ohta A, Koda T, Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000, 46(Suppl):S52-S61.
29. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 2000, 18:927-974. 10.1146/annurev.immunol.18.1.927, 10837079.
30. Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabongkot J, Torii M, Tsuboi T, Kumar N. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 2004, 22:3205-3213. 10.1016/j.vaccine.2003.11.060, 15297075.
31. Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol 1998, 160:1398-1404. 10.1016/S0022-5347(01)62548-5, 9751363.
32. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178:92-100. 10.1086/515613, 9652427.
33. Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 2004, 199:126-143. 10.1111/j.0105-2896.2004.00138.x, 15233731.
34. Marshall DJ, San Mateo LR, Rudnick KA, McCarthy SG, Harris MC, McCauley C, Schantz A, Geng D, Cawood P, Snyder LA. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother 2005, 54:1082-1094. 10.1007/s00262-005-0687-0, 16047142.
35. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004, 110:326-335. 10.1002/ijc.20116, 15095296.
36. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173. 10.1146/annurev.iy.07.040189.001045, 2523712.
37. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619-628. 10.1084/jem.20012142, 2193999, 12208877.
38. Tanaka M, Kaneda Y, Fujii S, Yamano T, Hashimoto K, Huang SK, Hoon DS. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther 2002, 5:291-299. 10.1006/mthe.2002.0537, 11863419.
39. Schirmbeck R, Reimann J. Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen. Biol Chem 2001, 382:543-552.
40. Tangney M, Ahmad S, Collins SA, O'Sullivan GC. Gene therapy for prostate cancer. Postgrad Med 2010, 122:166-180. 10.3810/pgm.2010.05.2154, 20463426.
41. Kusumanto YH, Mulder NH, Dam WA, Losen M, De Baets MH, Meijer C, Hospers GA. Improvement of in vivo transfer of plasmid DNA in muscle: comparison of electroporation versus ultrasound. Drug Deliv 2007, 14:273-277. 10.1080/10717540601098807, 17613014.
42. Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L, Hoglund U, Blomberg P, Fons M, Mathiesen I, Sallberg M. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007, 179:4741-4753.
43. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000, 165:2850-2858.
44. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164:4635-4640.
45. Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005, 62:217-223. 10.1002/pros.20135, 15389792.
46. Kuratsukuri K, Wang CY, Sone T, Nishisaka N, Jones RF, Haas GP. Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector. Eur Urol 2002, 42:67-73. 10.1016/S0302-2838(02)00211-7, 12121733.
47. Kuratsukuri K, Sone T, Wang CY, Nishisaka N, Jones RF, Haas GP. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer 2002, 102:244-249. 10.1002/ijc.10700, 12397643.
48. Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother 2007, 56:885-895. 10.1007/s00262-006-0241-8, 17102977.
49. Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006, 24:293-303. 10.1016/j.vaccine.2005.07.074, 16115700.
50. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther 2010, 8:1. 10.1186/1479-0556-8-1, 2829554, 20181099.
51. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009, 17:1101-1108. 10.1038/mt.2009.66, 2835175, 19337234.
52. Ahmad S, Casey G, Cronin M, Rajendran S, Sweeney P, Tangney M, O'Sullivan GC. Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen. J Urol 2011, 186:687-693. 10.1016/j.juro.2011.03.139, 21683415.
53. Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther 2006, 13:436-444. 10.1038/sj.cgt.7700914, 16276349.
54. Roos AK, King A, Pisa P. DNA vaccination for prostate cancer. Methods Mol Biol 2008, 423:463-472. 10.1007/978-1-59745-194-9_36, 18370222.
55. Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2010, 9:731-745. 10.1586/erv.10.64, 20624047.
56. Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S, Mincheff M. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 2005, 5:1.
57. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009, 20:1269-1278. 10.1089/hum.2009.067, 19619001.
58. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27:4047-4054. 10.1200/JCO.2008.19.9968, 2734418, 19636017.
59. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999, 48:353-362. 10.1007/s002620050586, 10501847.
60. Pawelec G. Tumour escape: antitumour effectors too much of a good thing?. Cancer Immunol Immunother 2004, 53:262-274. 10.1007/s00262-003-0469-5, 14685780.
61. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004, 53:844-854.
62. Tangney M, Casey G, Larkin JO, Collins CG, Soden D, Cashman J, Whelan MC, O'Sullivan GC. Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease. Cancer Immunol Immunother 2006, 55:1443-1450. 10.1007/s00262-006-0169-z, 16612593.
63. Mincheff M, Altankova I, Zoubak S, Tchakarov S, Botev C, Petrov S, Krusteva E, Kurteva G, Kurtev P, Dimitrov V, et al. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol 2001, 39:125-132. 10.1016/S1040-8428(01)00111-1, 11418309.